Barclays lowered the firm’s price target on Pfizer to $34 from $35 and keeps an Equal Weight rating on the shares spot the Q3 report. The analyst says the Street’s “myopic focus” on Danuglipron overshadows the solid core business performance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer Inc Earnings Update: Did it Beat Estimate Forecasts?
- Options Volatility and Implied Earnings Moves Today, October 31, 2023
- Pfizer (NYSE:PFE) Delivers Lackluster Q3
- Pfizer backs FY23 adjusted EPS view $1.45-$1.65, consensus $1.50
- Pfizer sees FY23 Paxlovid revenues of approximately $1B, down 95% from 2022
